Skip to main content
. 2019 Jul 10;366:l4217. doi: 10.1136/bmj.l4217

Table 2.

Summary of measures included in overall company transparency scores

Trial samples Measures % of trial sample score % of company score
Data sharing applicable trials Registration by deadline 6.7 33.3
Policy provides access to analysis ready dataset and clinical study report 6.7
Policy explains how data might be requested 6.7
Company reports number and outcome of data requests 6.7
Policy specifies data will be shared by deadline 6.7
Trials in patients Registration of trial and results publicly available by 6 months after primary completion date (reported or published) 33.3 33.3
Food and Drug Administration Amendments Act trials Registration by 21 days of trial start date and results reported by 30 days after approval by FDA of indication studied 33.3 33.3
Total   100 100